Bristol-Myers Squibb

BMYleader

Bristol-Myers Squibb is a global biopharmaceutical company with leading franchises in oncology and cardiovascular medicine. Eliquis is the world's best-selling oral anticoagulant and Opdivo is a top-selling cancer immunotherapy.

⇄ Compare

产品与营收

产品营收占比

营收构成 ($45.0B)

静态数据（加载实时财务…）

Oncology (42%)

Cardiovascular (33%)

Immunology (15%)

Other (10%)

业务板块构成与主要客户

产品详情

Eliquis30%

Blood thinner for stroke prevention in atrial fibrillation

Opdivo25%

Immuno-oncology checkpoint inhibitor for multiple cancer types

Revlimid15%

Treatment for multiple myeloma and other blood cancers

Other Specialty30%

Cardiovascular, immunology, and fibrosis therapeutics pipeline

供应链关系

竞争对手

Johnson & Johnson

Oncology, immunology drugs

影响: Major pharma competitor

主要客户

UnitedHealth Group

Formulary drug placements

影响: $3B+ annually

The Cigna Group

Drug coverage via Express Scripts

影响: $2B+ annually

宏观与市场背景

헬스케어行业新闻

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

近期催化剂

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

AI 分析

点击「获取 AI 分析」以获得 Bristol-Myers Squibb 的 AI 供应链分析。

企业信息

总部

New York, New York, USA

成立时间

1887

员工人数

34,000+

官网

bms.com

行业概况 — 헬스케어

行业新闻